Has Catherine McCarthy, MD received payments from drug or device companies?

Yes. Drug and device makers reported $68,474 in general payments to Catherine McCarthy, MD across 79 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Catherine McCarthy, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Catherine McCarthy, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Catherine McCarthy, MD

Family Medicine · Reno, NVNPI 1386600419

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $56,113 of the $68,474 with a category attached, or 81.9%. Organon accounts for 72.2% of it on its own, with 2 other manufacturers making up the rest. Among family medicine clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$68,474in general payments, 2019–2025

Across 79 payments — averaging $866.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Organon$49K
Merck$19K
Edwards Lifesciences$100

What the payments were for

Consulting fees$9,04513%
Speaking & faculty fees$56,11382%
Travel & lodging$2,6784%
Food & beverage$6381%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Organon	53	$49,452
Merck	25	$18,921
Edwards Lifesciences	1	$100

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,474 in reported general payments places this provider in the 95th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada →

Medicare billing

Part B allowed, 2024

$15,703

Medicare patients

Services billed

172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Mexiletine Hcl	12	$1,064
Levothyroxine Sodium	59	$866
Atorvastatin Calcium	42	$630
Lovastatin	22	$299
Rosuvastatin Calcium	18	$176
Metformin Hcl	21	$175
Lisinopril	22	$166
Olmesartan Medoxomil	13	$101
Tamsulosin Hcl	12	$96
Hydrochlorothiazide	11	$90
Gabapentin	13	$82
Amlodipine Besylate	12	$53

Paid to pharmacies, not to this prescriber.

Other family medicine in Reno

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →